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Randomized clinical trials (RCT) assessing the efficacy and tolerability of triptans compared with placebo as short-
term prophylaxis of menstrual migraine (MM) were systematically reviewed in this study. Triptans, which interfere
with the pathogenesis of migraine and are effective in relieving associated neurovegetative symptoms, have been
extensively proposed for prevention of menstrual migraine attacks. We searched Cochrane CENTRAL, MEDLINE and
EMBASE for randomized, double-blind, placebo-controlled trials on triptans for MM until 1 Oct, 2012. A total of six
RCTs were identified. Two authors independently assessed trial’s quality and extracted data. Numbers of participants
free from MM per perimenstrual period (PMP), requiring rescue medication, suffering from headache-associated
symptoms and experiencing adverse events in treatment and control groups were used to calculate relative risk
(RR) and number needed to treat (NNT) with their corresponding 95% confidence interval (CI). A total of 633
participants received frovatriptan 2.5 mg QD, 584 received frovatriptan 2.5 mg BID, 392 received naratriptan 1 mg
BID, 70 received naratriptan 2.5 mg BID, 80 received zolmitriptan 2.5 mg BID, 83 received zolmitriptan 2.5 mg TID
and 1104 received placebo. Overall, triptans is an effective, short-term, prophylactic treatment of choice for MM.
Considering MM frequency, severity and adverse events, frovatriptan 2.5 mg BID and zolmitriptan 2.5 mg TID tend
to be the preferred regimens.
Keywords: Meta-analysis, Systematic review, Frovatriptan, Naratriptan, Zolmitriptan, Menstruation, Migraine,
ProphylaxisReview
Introduction
Migraine, a primary headache disorder, is more common
in women (14.5-18%) than in men (4.5-6%) [1,2], and it
is often associated with sensory symptoms, nausea or
vomiting, and disability [3,4]. Female migraineurs fre-
quently experience headache in association with their
menstrual cycles [5,6], which is also known as menstrual
migraine (MM). MM includes menstrually-related mi-
graine, defined as migraine with menstruation as well as
at other times of the cycle, and pure MM, in which mi-
graine occurred only in association with menstruation
on or between day −2 to day +3 [7,8]. MM has been
reported to be longer, more disabling, less responsive to
acute therapy, and more prone to recurrence than non-
menstrual migraine attacks. Effective preventive strategies
are key for the management of MM [9-12]. Rofecoxib [13],* Correspondence: lingjingjin@hotmail.com
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in any medium, provided the original work is pestradiol [14,15], topiramate [16,17], magnesium [18],
nimesulide [19] and naproxen sodium [20] have been used
in the treatment of migraine.
Triptans, such as frovatriptan, naratriptan and zolmi-
triptan, are a class of highly selective serotonin receptor
agonists, which can interfere with the pathogenesis of
migraine and are effective in relieving the associated
neurovegetative symptoms [21-23]. They have been
recommended as first-line drugs for the treatment of
moderate to severe migraine, including MM [24,25]. In
recent years, triptans have been extensively proposed for
the prevention of menstrual migraine attacks.
To date, no systematic review has been done to inves-
tigate the efficacy and tolerability of triptans in the pre-
vention of MM. This review was undertaken to evaluate
the efficacy and tolerability of triptans at different doses
in randomized controlled trials (RCTs). Our findings
may offer an updated reasonable guide for the treatment
of MM in clinical practice.pen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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Studies
We searched the Cochrane Central Register of Controlled
Trials, Medline and Embase using the terms “migraine”,
“migraine disorders”, “prevention”, “prophylaxis”, ” men-
strual”, “menstrually” and “menses”. References of identi-
fied studies were further evaluated. Clinical trials before 1
October 2012 were collected for analysis. There was no
restriction on language, but we focused on studies that
had been conducted in humans and RCTs. Two authors
independently searched and selected studies, and then
extracted data from each study for further analysis.
Disagreements were resolved by discussion with another
author. A placebo comparator is essential to confirm the
effectiveness of triptans, and the comparisons were done
between triptan and placebo. MM was diagnosed accord-
ing to the criteria developed by the International Headache
Society (IHS) or other definitions that conformed in gen-
eral to IHS diagnostic criteria [8,26]. There was no restric-
tion on MM frequency, duration or type, dose or route of
administration, provided the medication could be self-
administered. Although there are a few studies suggesting
triptans are effective in the treatment of MM [27-30], data
of these studies were not included for analysis to minimize
potential confounder.
Statistical analysis
Methodological quality was assessed using the Oxford
Quality Scale [31]. Studies were analyzed using a single
dose of a triptan in reducing the incidence of MM, MM
severity, need for rescue medicine and adverse events.
The effect of the association was expressed as relative
risk (or ’risk ratio’, RR) with its corresponding 95% confi-
dence interval (CI). Pooled RR was estimated using the
fixed effects. Heterogeneity between studies was tested
using the Q statistic. Such heterogeneity was considered
statistically significant if a value of P<0.1 was present
[32]. Number needed to treat (NNT) with 95% CI was
used as absolute measures of benefit, termed number
needed to treat to benefit (NNTB), or harm, termed




Silberstein (2004) [33] USA 506 frovatriptan 2.5 mg QD
Brandes (2009) [7] International 410 frovatriptan 2.5 mg QD
Newman (2001) [34] USA 206 naratriptan 1 mg or 2.
Mannix (s1) (2007) [35] USA 287 naratriptan 1 mg
Mannix (s2) (2007) [35] International 346 naratriptan 1 mg
Tuchman (2008) [36] USA 244 zolmitriptan 2.5 mg BID
* intention-to-treat population.
** used Headache Society (IHS) 1988 criteria.included in this meta-analysis might differ slightly from
those in previous reports because we treated data in a
consistent manner across all trials. STATA version 12.0
(STATA, College Station, TX, USA) metan package (ver-
sion 1.86) was used for meta-analyses.
Results
Studies which were included in this study for analysis
are shown in Table 1.
Studies
Seven trials that met our inclusion criteria were identi-
fied, among which one [37] was excluded because its
data were included in one of the remaining 6 trials. All
the six trials (Table 1) were double-blind. Among them,
Silberstein’s trial (2004) was cross-over in design. All of
these studies focused on a single dose of a triptan in the
prevention of MM and were multicentred. The mean
age of participants ranged from 36 to 38 years, and all
were women.
All trials compared a triptan with placebo. No trials
directly compared one drug with another. Frovatriptan
2.5 mg QD and 2.5 mg BID were tested in two trials,
naratriptan 1 mg BID in three trials, and zolmitriptan in
one trial. In Newman’s trial (2001), two doses of nara-
triptan (1 mg, 2.5 mg) were administered. A total of 633
participants received frovatriptan 2.5 mg QD, 584
received frovatriptan 2.5 mg BID, 392 received naratrip-
tan 1 mg BID, 70 received naratriptan 2.5 mg BID, 80
received zolmitriptan 2.5 mg BID, 83 received zolmitrip-
tan 2.5 mg TID and 1104 received placebo.
Most trials evaluated the proportion of patients with-
out MM during the treated PMPs as the primary out-
come. Three of six trials evaluated the proportion of
patients using rescue medication and two evaluated the
severity of MM. Two of six trials evaluated the MM dur-
ation and MM associated symptoms in distinct ways.
Methodological quality, assessed using the Oxford
Quality Scale, was good in all studies. Except Tuchman’s
trial (2008) which scored 3/5 and Newman’s trial (2001)









or BID MAM** 6 −2 1
or BID MM 6 −2 3
5mg BID MAM** 5 −2 4
BID MRM** 6 −3 4
BID MRM** 6 −3 4
or TID MM** 7 −2 3
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method of randomization and blinding. All studies
reported withdrawals or dropouts. Sequence generation,
allocation concealment and blinding were assessed using
the “risk of bias” tool (Figure 1). No studies were at high
risk of bias.
Primary outcomes
For the primary outcomes of interest, we focused on the
proportion of patient free from MM during the treated
PMPs. Except Silberstein (2004), all the other trials
crossed more than one PMP, and thus being free from
MM per PMP was selected as our primary outcome.
The characteristics of MM including MM severity were
used as secondary outcomes.
Frovatriptan
Silberstein (2004) and Brandes (2009) tested frovatriptan
2.5 mg QD and BID. The relative benefit of frovatriptan
2.5 mg QD compared with placebo was 1.48 (1.27 to
1.72), giving an NNTB of 7.22 (5.25 to 11.54); that of
frovatriptan 2.5 mg BID compared with placebo was
1.82 (1.58 to 2.09), giving an NNTB of 3.90 (3.23 to
4.93). Patients with frovatriptan 2.5 mg BID had a 23%
increase in free from MM per PMP 1.23 (1.10 to 1.39),
giving an NNTB of 8.50 (5.77 to 16.19), compared with
frovatriptan 2.5 mg QD (Figure 2).
Naratriptan
Three trials (Mannix (s1) (2007), Mannix (s2) (2007),
Newman (2001)) tested naratriptan 1 mg BID. The rela-
tive benefit of naratriptan compared with placebo was
1.48 (1.20 to 1.83), giving an NNTB of 7.98 (5.24 to
16.71) (Figure 3). Only Newman (2001) using naratrip-
tan 2.5 mg BID reported that naratriptan treated
patients had fewer overall MMs and fewer MM days
compared with patients in the placebo group, however
no significant differences were found. The NNT for
naratriptan 2.5 mg BID was not calculated.Figure 1 Methodological quality assessment: methodological qualityZolmitriptan
Tuchman (2008), using zolmitriptan 2.5 mg BID and
TID reported that both zolmitriptan regimens demon-
strated superior efficacy vs placebo, as measured by ≥50%
reduction in the frequency of MM and the mean number
of breakthrough MM per menstrual cycle. There were in-
sufficient data for meta-analysis. The NNTBs for free from
MM per menstrual cycle zolmitriptan 2.5 mg BID versus
placebo, 2.5 mg TID versus placebo and 2.5 mg TID ver-
sus BID were 4.98 (3.26 to 10.57), 2.52 (1.95 to 3.58) and
5.11 (2.95 to 18.93) respectively.
All studies had scores of methodological quality of ≥ 3/5,
and no sensitivity analysis for primary outcomes was car-
ried out for this criterion.Secondary outcomes
For the secondary outcomes of interest, we focused on
MM severity, need for rescue medication, adverse
events.Frovatriptan
Patients with frovatriptan, both 2.5 mg QD and BID, had
a reduction in MM severity and need for rescue medica-
tion, and BID was superior to QD. Frovatriptan 2.5 mg
QD had a reduction in moderate to severe MM per
PMP (0.75 [0.67 to 0.85]) giving an NNTB of 7.70 (5.43
to 13.19), and in need for rescue medication per PMP
(0.79 [0.70 to 0.89]) giving an NNTB of 9.28 (6.17 to
18.72) when compared with placebo. Analogously, frova-
triptan 2.5 mg BID had a reduction in moderate to
severe MM per PMP (0.57 [0.50 to 0.66]) giving an
NNTB of 4.43 (3.58 to 5.81), and in need for rescue
medication per PMP (0.64 [0.56 to 0.74]) giving an
NNTB of 5.57 (4.28 to 7.99) when compared with pla-
cebo. Frovatriptan 2.5 mg BID vs QD had a reduction in
moderate to severe MM per PMP (0.77 [0.65 to 0.90])
giving an NNTB of 10.45 (6.72 to 23.44), and in need for
rescue medication per PMP (0.81 [0.70 to 0.94]) giving
an NNTB of 13.93 (7.94 to 56.73) (Figure 4).presented as percentage across all studies.
Figure 2 Forest plot: free from MAM per PMP in trials on frovatriptan.
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cebo, frovatriptan 2.5 mg BID vs placebo and frovatrip-
tan 2.5 mg QD vs BID were comparable. Most reported
adverse events were mild to moderate. The incidence of
severe adverse events was low and appeared to be unre-
lated to the treatments [7,33].
Naratriptan
Because the changes in MM severity and need for rescue
medication were not mentioned in trails on naratriptan,
we focus on adverse events and drug-related events as
the secondary outcomes of trials on naratriptan. After
treatment with naratriptan 1 mg BID, there was an
increase in adverse events (1.37 [1.10 to 1.70]) giving an
NNTH of 10.88 (6.46 to 34.38), but drug-related eventsFigure 3 Forest plot: free from MAM per PMP in trials on naratriptan(1.69 [0.98 to 2.90]) were comparable to the placebo
(Figure 5). Newman (2001) using naratriptan 2.5 mg BID
reported that the overall adverse events and drug-related
events were similar to those in placebo group. In all
studies, serious drug-related adverse events were not
reported [34,35].Zolmitriptan
Tuchman (2008) reported both zolmitriptan 2.5 mg
BID (0.82 [0.71 to 0.94], giving an NNTB of 7.31 [4.32
to 23.81]) and zolmitriptan 2.5 mg TID (0.83 [0.71 to
0.97], giving an NNTB of 7.81 [4.31 to 41.64]) demon-
strated a reduction in the need for rescue medication
when compared with placebo.1 mg BID.
Figure 4 Forest plot: secondary outcomes of frovatriptan.
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adverse event across 4 PMPs (1.44 [1.03 to 2.01]), giving
an NNTH of 7.81 (4.31 to 41.64) when compared with
placebo (Figure 6). Five serious adverse events were
reported during the preventative therapy: two in the zol-
mitriptan 2.5 mg TID group (pyelonephritis and endo-
metrial disorder), two in the zolmitriptan 2.5 mg BID
(uterine neoplasm and anxiety) and one in the placebo
group [36]. When drug-related adverse events were
valued, no significant difference was found between
treatment group and control group.
Data of specific adverse events was too few for analysis
and was not consistently reported in these studies, so we
just list the most commonly adverse events for all the
three triptans in Table 2.Discussion
Summary of main results
In this systematic review, six trials were included, and
we compared the frovatriptan, naratriptan and zolmitrip-
tan at different doses with placebo in preventing MM.
We employed explicit and systematic methods to iden-
tify, select and critically appraise studies, and to extract
data followed by a meta-analysis. Frovatriptan was given
to 633 participants at 2.5 mg QD and to 584 participants
at 2.5 mg BID and 646 participants were treated with
placebo. Naratriptan was given to 462 participants at 1
mg or 2.5 mg BID who were compared with 377 placebo
treated participants. In addition, 80 participants received
zolmitriptan 2.5 mg BID, 83 received zolmitriptan 2.5
mg TID and 81 received placebo. In all trails, triptans
Figure 5 Forest plot: secondary outcomes of naratriptan 1 mg BID vs placebo.
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triptans were more effective than placebo in the preven-
tion of MM.
All of the three triptans, including frovatriptan nara-
triptan and zolmitriptan, were more effective than pla-
cebo in reducing the MM frequency per PMP. The
incidence of moderate to severe MM per PMP and the
need for rescue medication occurred less often with fro-
vatriptan than with placebo. Patients with zolmitriptanFigure 6 Forest plot: secondary outcomes of Zolmitriptan.had less need for rescue medicine than placebo treated
patients. One of the putative benefits of preventative
therapy for MM with triptans is to reduce the severity of
MM attacks. As the NNTBs for frovatriptan 2.5 mg BID,
naratriptan 1 mg BID, zolmitriptan 2.5 mg TID in redu-
cing the incidence of MM per PMP were 3.90 (3.23 to
4.93), 7.98 (5.24 to 16.71) and 2.52 (1.95 to 3.58),
respectively, zolmitriptan and frovatriptan tended to be
more effective than naratriptan.
Table 2 Incidence of most commonly reported adverse
events
Treatment Placebo












Naratriptan 1 mg BID n=71 n=68
Dyspeptic symptoms 4.23% 0.00%




Naratriptan 2.5 mg BID n=71 n=68
Dizziness 4.23% 1.47%
Chest symptoms 2.82% 2.94%
Malaise and fatigue 2.82% 2.94%
Hyposalivation 2.82% 0.00%
Parasthesia 2.82% 0.00%
Burning/stinging sensations 2.82% 0.00%







Dry mouth 1.25% 1.22%







Dry mouth 5.95% 1.22%
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mon in triptans treated patients. However, when drug-
related events were taken into account, there were no
significant difference between triptans group and pla-
cebo group. Adverse events were generally mild to mod-
erate and rarely led to withdrawal. Studies on triptan at
one or two doses were underpowered for investigating
the specific adverse events, and studies with longer dur-
ation are required to determine the adverse event pro-
files of triptans in the treatment of MM. However, the
safety and tolerability of triptans in preventing migraine
had been well established. Considering MM frequency
and adverse events, frovatriptan 2.5 mg BID and zolmi-
triptan 2.5 mg TID are preferred for the prevention of
MM.
One interesting finding was that the efficacy of trip-
tans in prevention migraine was dependent on their con-
centrations. There were insufficient data to establish a
clear dose–response curve. However, frovatriptan 2.5 mg
BID tended to be better than frovatriptan 2.5 mg QD in
reducing headache during PMP, and zolmitriptan 2.5 mg
TID better than zolmitriptan 2.5 mg BID. These suggest
the efficacy of triptans is concentration and time-
dependent. Does it mean that higher dose or frequency
will bring better effect? In trials on naratriptan which
has a half-time of 6 h [35], naratriptan 1 mg BID was
statistically superior to naratriptan 2.5 mg BID. This im-
plies that the efficacy of triptans in prevention of mi-
graine depends on their concentrations. Considering
that frovatriptan has a long half-life (26 h [33]) and zol-
mitriptan posses a short half-life (3 h [38]), the fre-
quency and dose should be adjusted when a triptan is
used in the prevention of MM.
Overall completeness and applicability of evidence
Interpretation of these results is limited by the small
number of studies (n=6) which only included three
drugs at two doses. There were inadequate numbers of
participants and events to draw firm conclusions about
possible differences among different drugs or doses.
Because the enlistment of trials was through clinics,
this is likely to underestimate the therapeutic effect.
Clinics may select participants whose MM are more se-
vere, resistant to treatment than in the general popula-
tion. On the other hand, these participants may be more
motivated than the population as a whole.
In the available trials, triptans were used at safe doses
while still experiencing clinically useful levels of efficacy.
This may mean limitation on effective treatment; maybe
combined therapy with adjunctive drugs, such as estra-
diol or topiramate, might increase the effectiveness.
In this review, data related to migraine attacks be-
tween menses were not identified. This overlooks the
possibility, even very small, that preventative therapy
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are needed to monitor migraine attacks in menses and
to establish the differences among different triptans and
different doses. Long-term studies are also required to
determine the safety and tolerability. Further studies
comparing triptans with alternative drugs, such as estra-
diol or topiramate, are allowable to determine the rela-
tive benefits and harms.
The cost of triptans for MM prevention should also be
taken into consideration. Each triptan is much more
expensive than other prophylactic medications for mi-
graine (such as beta blockers, tricyclic antidepressants,
sodium valproate, and methysergide) [39]. At the same
time, menstrual cycles have natural variability, and even
in women whose menstrual cycles are regular, very few
invariably attacks have associated with their periods.
These infectors inevitably expose women to the use of
medication during cycles in which they would not have
a headache. Thus, only MM women who do not achieve
adequate relief from acute therapies may become candi-
dates for short-term preventative therapy with a triptan,
particularly if they experience regular menstrual mi-
graine attacks causing significant disability. In this way,
MM attack frequency is decreased, and these patients
have the opportunity to regain the days lost each month
through disability.Quality of the evidence
All studies were good in methodological quality and
scored above the minimum required to minimize bias.
IHS criteria or other definitions that generally con-
formed to IHS diagnostic criteria were used for the diag-
nosis of MM in all trials, and well-defined outcomes
were reported for the efficacy and tolerability.Conclusion
Current RCTs suggest that triptans treatment is an ef-
fective, short-term, prophylactic strategy for the manage-
ment of MM. Considering MM frequency, severity and
adverse events, frovatriptan 2.5 mg BID and zolmitriptan
2.5 mg TID are preferred for the treatment of MM.
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